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Highlights 
 Clara Szego reported rapid estrogen signaling over 50 years ago. 
 GPR30 cloned in 1992 in a search for novel GPCRs. 
 Renamed GPER as estrogen-mediated actions were discovered. 
 Therapeutic targeting of GPER in a multitude of chronic diseases. 
 Personal accounts on discoveries of GPER biology and functions. 
 
Abstract  
 
Estrogens play a critical role in many aspects of female physiology, particularly reproductive 
function, but also in pathophysiology, and are associated with protection from numerous 
diseases in premenopausal women. Steroids and particularly estrogen action have been known 
for ~90 years, with the first evidence for a receptor for estrogen presented ~50 years ago.  The 
original ancestral steroid receptor, extending back into evolution more than 500 million years, 
was likely an estrogen receptor, whereas G protein-coupled receptors (GPCRs) trace their 
origins back into history more than one billion years. The classical estrogen receptors (ER and 
ER) are ligand-activated transcription factors that confer estrogen sensitivity upon many 
genes. It was soon apparent that these, or novel receptors may also be responsible for the 
‘”rapid”/“non-genomic” membrane-associated effects of estrogen. The identification of an 
orphan GPCR (GPR30, published in 1996) opened a new field of research with the description 
in 2000 that GPR30 expression is required for rapid estrogen signaling. In 2005-2006, the field 
was greatly stimulated by two studies that described the binding of estrogen to GPR30-
expressing cell membranes, followed by the identification of a GPR30-selective agonist (that 
lacked binding and activity towards ER and ER).  Renamed GPER (G protein-coupled 
estrogen receptor) by IUPHAR in 2007, the total number of articles in PubMed related to this 
receptor recently surpassed 1000.  In this article, the authors present personal perspectives on 
how they became involved in the discovery and/or advancement of GPER research. These 
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areas include non-genomic effects on vascular tone, receptor cloning, molecular and cellular 
biology, signal transduction mechanisms and pharmacology of GPER, highlighting the roles of 
GPER and GPER-selective compounds in diseases such as obesity, diabetes, and cancer and 
the obligatory role of GPER in propagating cardiovascular aging, arterial hypertension and 
heart failure through the regulation of Nox expression. 
 
Key words: estrogen, GPCR, history, IUPHAR, non-genomic, pathology, pathophysiology, 
physiology, Charles-Édouard Brown-Séquard, Rudolf Chrobak, Adolf Butenand, Edward Doisy, 
Ferdinand Mainzer, Clara Szego, Adolf Windaus 
 
 
Introduction: Discovery of estrogens and their receptors    
 
Estrogens play critical roles in female biology and specifically reproductive function. They are 
also important in pathophysiology, playing an important role in breast cancer and protection 
from numerous diseases in premenopausal women [1-10]. In 1889, the French-Irish-American 
physiologist Charles-Édouard Brown-Séquard (1817-1894), at the age of 72, injected himself 
with crushed guinea pig and dog testicles, and noticed a "renewal of vigour and mental clarity" 
[11]. Brown-Séquard also reported in 1889 that a surgeon in Marseilles by the name of 
Villeneuve had administered a fluid made from guinea pig ovaries to one male and two 
postmenpausal female patients, one of whom was cured from her postmenopausal symptoms 
by the treatment. He further reported in the same year that a midwife in Paris had injected 
herself with the filtered juice of guinea pig ovaries leading to therapeutic "benefit", and that an 
American medical women named Augusta Brown (apparently not related to his family), a 
graduate at the University of Paris, had injected more than a dozen aged women with the 
filtered juice of guinea pig ovaries with good effects in hysteria, various uterine affections, and 
debility due to age [11].  Around the same time, on November 30, 1889, Rudolf Chrobak (1843-
1910) in Vienna orally administered freshly minced bovine ovary tissue to a 47 year-old women, 
albeit with little effect [12]. By contrast, Ferdinand Mainzer (1871-1943), at the time a medical 
resident, reported in 1896 on the beneficial effects of oral treatment with "Ovarialsubstanz" (a 
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concentrated extract made from porcine or bovine ovaries) of ovariectomized or 
postmenopausal women [13, 14], and likely described the first rapid effects related to estrogen: 
"the condition improved immediately after administration of Ovarialsubstanz" [13]. Similar 
findings were also reported by Landau [15] and Mond [16].  
 
It was at this time that molecular medicine appeared on the horizon, long before the genetic 
code was deciphered or medical genetics were known. Already in the early 1890s Canadian 
physician Sir William Osler (1849-1919) at Johns Hopkins University in Baltimore had identified 
hereditary patterns in families with coronary artery disease [17], and in 1894 the German 
pathologist Rudolf Virchow, considered the “father of modern pathology” [18, 19] proposed 
changing the prevailing dogma in anatomy, pathology and disease development, foreseeing the 
future of cellular and molecular biology and current modern medicine - concepts that were fully 
compatible with the observations of early endocrinologists discussed above [13-21]. Virchow 
presented his revolutionary views in a lecture presented at the XI International Medical 
Congress in Rome on March 30, 1894, which he ended with the following words: “…The idea of 
the ‘sedes morborum’, or, as I have designated it, ‘the anatomical concept’. It is this thought 
that governs the physiology and pathology of today. Whether it leads one back to the cells, as it 
does me, or whether another formula is developed, it will surely remain the concept for the 
future. And this future will mark the beginning of its chronology in the days of Morgagni. Let him 
be honoured!.” [22]. Ironically, the journal in which Virchow’s lecture was published (Berliner 
Medizinische Wochenschrift) merged with Therapeutische Monatsheft in 1922 to become 
Klinische Wochenschrift, and in 1995 changed its name to the Journal of Molecular Medicine 
[23]. 
 
It is worth noting that the chemical identity of steroids and particularly estrogens has only been 
known for less than a century, work that is largely owed to the American Edward A. Doisy 
(1893-1986) and the German Adolf Butenand (1903 to 1995), both of whom, in 1929, 
simultaneously discovered estrone [24-27]. At the time, Butenand was 26, having obtained his 
PhD only two years earlier in Göttingen with Adolf Windaus (1876 to 1956), the Nobel Laureate 
in Chemistry in 1928 for the discovery of vitamin D and sterols [28]. By 1935, Butenand had 
also identified progesterone and testosterone; Doisy later also isolated 17-estradiol and estriol 
[27, 29, 30]. Of note, both discoverers of estrogens also went on to win a Nobel Prize. 
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Butenand received the Nobel Prize in Chemistry in 1939, and Doisy was awarded the Nobel 
Prize in Physiology or Medicine in 1943 [27, 30]. 
 
The first evidence of a receptor for estrogen was presented by Elwood V. Jensen (1920-2012) 
in the 1950s [29, 31, 32]; however, it took 30 more years until the gene sequence of the first 
nuclear estrogen receptor was cloned [33-35].  In 2016, the Hungarian-American biologist Clara 
M. Szego (Figure 1) celebrated her 100th birthday. Fifty years earlier, Szego reported increases 
in cAMP production following acute exposure to estrogen [36]. In the following years Szego 
found the uterine cAMP increase to be inhibited by glucocorticoids [37] and  blockers (only if 
the adrenals were intact) [38], and also purified an estrogen receptor protein, demonstrating 
inhibition of its function using antibodies [39]. Ironically, it was again Szego, who in 1977 first 
reported estrogen receptors in plasma membrane fractions [40], which she later partially 
purified and characterized [41, 42]. In the 1980s, the cDNA sequence of first estrogen receptor 
(today known as ER) was determined [33-35], and by the mid 1990s, both the second nuclear 
estrogen receptor (today known as ER) and an orphan receptor designated GPR30 were 
cloned [43-50]. Initially believed to represent a GPCR for cytokines, the function(s) of GPR30 
remained elusive until recently. In the following sections, the individual authors will summarize 
their personal history and perspectives in this field. 
 
GPER in hiding: rapid effects of estrogen      
M. Barton  
 
One of the clinical observations for centuries had been that premenopausal women are largely 
protected from coronary artery disease and its clinical manifestations [51]. I began my work in 
the field of coronary artery disease and atherosclerosis in 1990 at the Division of Cardiology at 
Hannover Medical School in Germany, headed by the Swiss physician Paul R. Lichtlen (1929-
2005). In the 1960s, Lichtlen had pioneered coronary angiography in Europe at the University of 
Zürich and moved to Hannover in 1973 [52]. My studies, supported by Andreas Mügge and the 
cardiothoracic surgeons, were centered around the question of whether estrogen may exert 
acute vasodilatory effects on human coronary arteries. Human physiology studies had indirectly 
suggested the existence of rapid effects of estrogen in peripheral veins [53], but they had not 
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been demonstrated for human arteries. At the time, the identity of endothelium-derived relaxing 
factor (EDRF) as nitric oxide (NO) had just been discovered [54-56], and only one estrogen 
receptor (today known as ER) had been cloned [33-35]; whether this or additional estrogen 
receptors were involved in the regulation of vascular tone was not known.  
 
During my studies, which took more than three years to complete, it turned out that within 
minutes, 17-estradiol causes relaxation of human coronary arteries (Figure 2) of both women 
and men [57]. Results also showed that a 30-minute exposure to 17-estradiol indirectly 
improved vasodilation by enhancing endothelium-dependent relaxation [58]. At the time Lichtlen 
invited me to participate in my first scientific meeting, a small «International Workshop on 
Atherosclerosis» that he organized on October 9-10,1992 in Celle, Germany. Participants 
included many notable physician-scientists such as Gustav V. Born (b. 1921), Christian C. 
Haudenschild, Philippe D. Henry (1935-2013), Helmut Drexler (1951-2009) Elizabeth G. Nabel, 
David G. Harrison, as well as Peter Ganz, who at the time was also conducting studies on 
vascular effects of estrogens in humans, which he published in 1994 [59]. 
 
In search of the underlying mechanisms to help explaining the observed rapid vasodilatory 
response, I came across Clara M. Szego's early studies showing induction of cAMP production 
following acute estrogen exposure [36]. To investigate whether the observed rapid vascular 
effects involved any changes in cAMP production, I set up similar experiments human coronary 
arteries with help from Michaela Kuhn, an expert in cyclic nucleotide biology, demonstrating that 
within 30 minutes of application - the time required to induce full arterial relaxation - 17-
estradiol increased vascular cAMP content [57], both observations that could neither be 
explained by genomic mechanisms [60], nor by activation of the endothelial L-
arginine/NO/guanylate cyclase pathway. In the following year, Benita Katzenellenbogen, 
utilizing intact uterine tissue, also reported rapid increases in cyclic AMP content after a 30-
minute exposure to 17-estradiol [61]. Two years later, cloning of a second nuclear estrogen 
receptor was reported and named ER [62, 63], as was GPR30 [44], albeit as an orphan 
receptor without known ligand at the time. 
 
Meanwhile, following the advice of Paul Lichtlen and with his support, I had moved to 
Switzerland continuing my research in this area and began working on estrogen receptors [64, 
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65]. In 2002, a young medical student by the name of Matthias Meyer joined my group and we 
agreed that he would also study acute effects of estrogen on human vascular tissue. Meyer 
started his research (for which he later received the Medical Faculty's Best Thesis Award at the 
University of Zürich) and approached me one day, holding a print-out of an article, asking me 
whether I had seen the paper. It was a article by Eric Prossnitz's group from the University of 
New Mexico reporting the identification of GPR30 as an intracellular transmembrane estrogen-
binding receptor acting through PI3-kinase, thus identifying it as a third bona fide estrogen 
receptor [66]. I immediately thought back to my own studies from the early 1990s and realized 
that this receptor might explain part of the acute effects of 17-estradiol on cyclic AMP 
observed back then, and perhaps also the vascular relaxation. Meyer proposed to also study 
GPR30 expression in his experiments. He found that human blood vessels indeed express 
GPR30, which was sensitive to regulation by estrogen. Meyer reported his observations as 
unpublished data in April 2006 in his first peer-reviewed article [67]. The full data were 
published in a research report [68] that I dedicated to Paul Lichtlen, who had died in 2005, the 
same year we had started our work on GPER. 
  
In 2006, I contacted Prossnitz who agreed to share his GPER-specific ligands with us. In 
addition, I was fortunate to obtain mice lacking the Gper gene (generated by Jan Rosenbaum 
[69]) from Debbie Clegg, who was then at the University of Cincinnati, and was also introduced 
to Cristina and Eugen Brailoiu, experts in calcium biology at Temple University, and physiologist 
Tom Resta, at UNM.  Together, we published a report in January 2009 showing that GPER acts 
as an intracellular membrane receptor controlling cell proliferation, that it acutely reduces 
vascular tone and blood pressure, and that its genetic deletion leads to abdominal obesity [70]. 
We have since developed a very productive collaboration with Prossnitz and our studies – most 
of them performed by Meyer with enormous curiosity and persistence – led to the identification 
and characterization of multiple new, particularly genomic roles of GPER in cardiovascular 
function and disease which we will discuss elsewhere in this issue [71]. Looking back, without 
Paul Lichtlen’s mentoring, support, and trust in a young colleague, we might have never 
known… 
 
Cloning of an orphan GPCR named GPR30    
S. Lolait   
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The initial success in cloning G protein-coupled receptors (GPCR) was based on targeted 
approaches that relied predominantly upon biochemical purification of the receptor protein or on 
expression cloning where prior receptor sequence knowledge was not required. With the 
realization that GPCRs had a topography of 7 transmembrane (TM) domains and displayed 
varying degrees of conservation between and across GPCR subclasses, homology cloning 
came to the fore. This was facilitated by PCR and augmented by bioinformatics analysis of 
various genomes.  
 
GPR30 started off as an orphan GPCR with no known endogenous (or exogenous) ligand, one 
of many isolated by numerous labs in the late 1980’s - early 1990’s. My first foray into the 
GPCR that was later to be named GPR30/GPER began in late 1991 whilst working at the 
National Institutes of Mental Health (Bethesda, MD, USA). My colleague Christer Owman and I 
used PCR with degenerate primers to TM domains of known GPCRs to isolate a number of 
novel GPCR sequences from a human B-cell lymphoblast cDNA library. The full-length cDNA 
clones were isolated by February 1992 (Figure 3) - one of these was eventually named 
CMKRL2 (chemokine related receptor like 2) given its closest homology (approx. 30% overall 
amino acid identity) to chemokine GPCRs, but it did not respond to a battery of chemokines 
when expressed in cell lines [44]. GPR30 ‘re-emerged’ in our lab a few months later in mouse 
form when I used a similar PCR-based strategy to isolate a novel GPCR cDNA clone (AtT20#9) 
from a murine AtT20 pituitary tumor cDNA library. Cell lines expressing the corresponding full-
length clone did not respond to the peptide ligands in which I was interested at the time (e.g., 
corticotropin releasing factor, vasopressin) so the clone went to the back of the freezer. 
Parenthetically, we were interested in fast steroid responses in the lab around this time - there 
were numerous futile attempts to elicit rapid elevations in intracellular Ca2+ levels in response to 
estrogen, aldosterone or corticosterone in Xenopus oocytes expressing both the Ca2+-sensitive 
photoprotein aequorin and mRNAs isolated from various tissues and cells. We never tested 
whether cell lines stably expressing our human or mouse GPR30 clones responded to 
estrogen. 
 
The cloning of CMKRL2 published in 1996 [44] was closely followed over the next year or so by 
independent reports of the isolation of the same human orphan GPCR cDNA under various 
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aliases (e.g., CEPR, LyGPR, FEG-1, GPCR-Br [46-50]) and a rat homologue GPR41 [45]. The 
GPR30 designation was adopted [46, 50] following on from the consecutive numbering of 
previous GPCR orphans reported in the literature. The cloning of most of the GPR30s was 
based on PCR with degenerate primers to highly conserved TM regions of known GPCRs, 
using libraries constructed from cDNA or genomic DNA (as most GPCR genes are intronless or 
contain very few introns in their open reading frame) as a template. One exception was a 
GPR30 cDNA sequence deposited in GenBank as 'DRY12' (accession number U58828) in mid-
1996 that resulted from an effort to expression clone a receptor for 1-antitrypsin-protease 
complexes (David Perlmutter, personal communication, 2016). In addition, GPCR-Br/GPR30 
was obtained by differential screening of an MCF7 breast tumor cell cDNA library with cDNA 
probes from estrogen receptor (ER)-positive and ER-negative tumor cell lines. This was the first 
clue that GPR30 might be related to estrogen responsiveness [46]. 
 
The studies noted above showed that the human GPR30 gene maps to chromosome 7 and 
lacks introns in its protein-coding portion.  Its translated DNA sequence (open reading frame) 
predicts a 375 amino acid protein that has consensus sites for possible post-translational 
modification (e.g., glycosylation, phosphorylation) and the structural signature of the Class A 
Rhodopsin-like GPCR subfamily (e.g., it has a ‘DRY’ amino acid motif at the tail of TM3). It is 
ubiquitously expressed as a 2-3kb mRNA transcript in brain regions (e.g., hypothalamus and 
hippocampus) and peripheral tissues such as placenta, prostate, lung, heart, liver and lymphoid 
tissue, and is particularly abundant in some lymphocyte cell lines (but less so in purified 
lymphocytes) and vascular endothelial cells subjected to shear stress [49]. Gene expression 
profiles, useful in the deorphanisation of some GPCRs (e.g., cannabinoid CB1 receptor [72]), 
especially when performed in an anatomical context at the cellular level, provided little insight 
into a possible endogenous GPR30 ligand.  
 
I discovered in mid-late 2000, when performing DNA sequence comparisons (NCBI BLAST), 
that our murine AtT20 and human lymphoblast cDNA clones were species homologues - up 
until that time I had never compared the two translated protein sequences! To my surprise a 
study had also reported that GPR30-associated intracellular pathways were activated by 
estrogen [73]. Given my interest in rapid steroid effects, the irony that I had not tested estrogen 
on our orphan GPCR clones did not escape me!!  
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Molecular biology of GPR30 and its rapid effects  
E. J. Filardo   
 
To play an integral role in the development of a paradigm-shifting idea built by collegial 
interaction is truly a rewarding experience.  My contribution towards the idea that GPCRs 
promote pre-genomic signaling by sex steroid hormones was rooted in my postdoctoral work in 
David Cheresh’s lab at Scripps Research Institute.  Unbeknownst to me, Eric Prossnitz (also at 
the early stages of his scientific career) was working at the same time in Charlie Cochrane’s 
group, at his lab bench a mere 10 yards from mine.  Although we did not collaborate or interact 
while at Scripps, both of us were working on structure/function relationships centered upon 
transmembrane receptors and intracellular signaling. The intersection of our work was not as 
obvious then as it is now. While my work focused on the molecular basis of bidirectional 
signaling by integrins [74-76], Eric was working on structure-function relationships of 
chemoattractant receptors of the GPCR superfamily.  
 
My journey towards GPR30 began with my interest in the work by Keith Yamada that described 
“rapid”, pre-genomic intracellular signaling networks activated by integrin occupancy and 
aggregation [77, 78], and a body of literature that had linked GPCRs and RTKs to integrin 
function. At that time, little was known about how estrogen, or other steroid hormones, 
manifested rapid intracellular signals associated with growth factor-like responses and 
extracellular matrix interactions, essential cellular responses necessary for tissue homeostasis 
and cell survival. Offered an opportunity to begin my independent career in 1996 by Dr. Kirby 
Bland at the Brown University School of Medicine, I became interested in understanding the 
role of estrogen in promoting epidermal growth factor and integrin activation, and its possible 
importance to breast cancer pathophysiology. A literature review confirmed for me the difficulty 
in aligning pre-genomic responses by estrogen with the known structure-function relationships 
assigned to ER and other members of the nuclear steroid hormone receptor family. 
 
By the late 1990s, many laboratories had implicated GPCRs and/or G proteins in estrogen-
mediated activation of cAMP and other second messengers [79]; however, the mechanism that 
linked estrogen to protein kinase signaling was entirely unclear. Robert Lefkowitz [80], and Axel 
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Ullrich [81] provided a molecular mechanism by which a single GPCR could trigger, in parallel, 
second messenger and EGFR-mediated signaling pathways through activation of G- and G- 
dependent signaling mechanisms. Based on these findings, I became intrigued by the idea that 
an orphan GPCR, whose known ligand had yet-to-be identified, could serve as a singular 
receptor mechanism capable of activating second messenger and protein kinase pathways.  
While earlier investigators evaluating pre-genomic estrogen signaling relied solely on ER-
positive cell models, I was keen on including ER-negative breast cancer cell models in our 
analysis. A colleague of mine at Brown, Raymond Frackelton, an expert in EGFR signaling, was 
a key contributor to these early experiments and pointed out that human SKBr3 breast cancer 
cells were negative for ER and its recently cloned homologue ER, at the level of RT-PCR. I 
remember my surprise, when Jeffrey Quinn from my lab showed me the results that estrogen 
was capable of promoting EGFR tyrosine phosphorylation in SKBr3 breast cancer cells as well 
as ER-positive MCF-7 cells.  Yet, we observed that the same response was not detected in ER-
negative MDA-MB-231 cells despite the fact that EGF stimulation led to potent EGFR activation 
in these cells. I must have asked Jeff to repeat these experiments at least a dozen times! We 
were even more surprised that ER antagonists also triggered EGFR activation in SKBr3 cells 
and these data suggested to us that the mechanism of action was clearly ER-independent.  
 
GPR30 was isolated as a molecular clone by different laboratories and received its orphan 
designation because its cognate ligand had yet to be identified. We noticed that it was cloned 
from breast cancer, cardiovascular tissue, brain and other estrogen-responsive tissues [44, 46-
50]. We were particularly interested in the fact that it had been isolated by subtractive cloning 
from breast cancer lines that displayed differences in their competence for pre-genomic 
signaling by estrogen [46], causing us to consider the possibility that GPR30 may serve as an 
estrogen receptor. A phone call to Ron Weigel resulted in the use of his GPR30 molecular 
clone in marker rescue experiments to test the concept that GPR30 may trigger G- and G-
dependent activation of adenylyl cyclase and EGFR tyrosine kinase activity [73, 79]. Interested 
in determining whether we could measure specific estrogen binding associated with GPR30, I 
contacted Peter Thomas, a comparative endocrinologist with expertise in steroid membrane 
receptor binding. We had a nice telephone conversation and were excited about designing 
experiments that would test the possibility that GPR30 may provide an evolutionarily conserved 
ER-independent mechanism of estrogen signaling. Through the use of a traditional radioligand 
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binding assay, Peter and I were able to link estrogen binding activity to GPR30 expression in 
enriched plasma membrane preparations isolated from tissues derived from both man [82, 83] 
and fish [84]. Key to the strength of these data was the observation that uncoupling Gs from 
GPR30 significantly reduced ligand binding [82, 84]. Studies from the Prossnitz lab using an 
independent approach showed the association of specific GPR30 binding by fluorescently-
labeled estrogen derivatives [66] and that selective synthetic agonists/antagonists discriminate 
GPR30 from ER [85, 86], helping to further establish the concept that GPR30 is an estrogen 
receptor, and leading to its description as an estrogen receptor now known by its IUPHAR 
functional designate as GPER [87].  
 
To date, the most vexing part of understanding the molecular mechanism of GPER has been 
the observation that its expression is commonly, but not exclusively localized to intracellular 
membranes in many tissues. Endogenous GPER is expressed on the cell surface in certain 
tissues, including oocytes, pyrimadal neurons and cortical renal epithelia [88]. GPER is not 
alone in this regard, as many GPCRs show a predominantly intracellular expression pattern and 
have been shown to function intracellularly [89], particularly following internalization [90], but 
also on nuclear, Golgi apparatus and endoplasmic reticulum membranes [91, 92]. 
Nevertheless, the mechanisms that limit GPCR surface expression at the plasma membrane 
also represent a primary means to dictate cellular responsiveness of many GPCRs to their 
cognate ligands, particularly those that are not membrane permeable in contrast to lipids and 
steroids. For this reason, studies that investigate the molecular mechanisms that determine the 
subcellular distribution of GPER are the next critical step in understanding its mechanism of 
action, and may be vital in developing effective pharmacological agents that target this novel 
estrogen receptor. 
 
Binding and signal transduction of GPER 
P. Thomas   
 
I became interested in nongenomic steroid actions in 1980 when I began investigating the 
endocrine control of oocyte meiotic maturation in fish. Recent studies in fish and amphibians 
had indicated that a maturation–inducing steroid (MIS) acts on the oocyte surface through a 
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membrane receptor to induce meiotic maturation by a transcription-independent mechanism 
[93, 94]. Reynaldo Patino developed a reliable membrane receptor filtration assay for 
measurement of MIS receptor binding in our laboratory [95], which proved to be indispensable 
for our subsequent studies to identify novel steroid receptors. The assay was used to track MIS 
receptor binding by Yong Zhu during the purification, cloning and characterization of the 
membrane progestin receptor α (mPRα), which belongs to the progestin adipoQ receptor 
(PAQR) family, and is the first steroid receptor unrelated to nuclear steroid receptors discovered 
in vertebrates [33,34,35]. Modifications of the receptor assay were later used in our laboratory 
by Hakan Berg to track androgen binding during purification, cloning and characterization of the 
novel membrane androgen receptor, ZIP9, a zinc transporter protein belonging to the SLC39A 
family [36,37] 
         
Fortunately, the lengthy procedures we used to identify mPRα and ZIP9 were not required to 
identify the novel membrane estrogen receptor (ER) because a candidate, the orphan GPCR, 
GPR30, had already been identified by Edward Filardo [73].  He had identified GPR30 as a 
potential membrane ER based on his pioneering research on estrogen stimulation of adenylyl 
cyclase/cAMP and EGFR/MAPK signaling in GPR30-positive, nuclear estrogen receptor (ER)-
negative breast cancer cells [73, 79, 96].  We gladly accepted Ed’s invitation to participate in a 
collaborative research effort to determine if human GPR30 is a membrane ER. A 17β-estradiol 
(E2) binding activity with all the characteristics of a membrane ER was identified on SKBR3 cell 
membranes, which express GPR30 but lack full-length nuclear ERs, and in ER-null HEK293 
cells transfected with GPR30, using our well-characterized receptor assay for croaker 
membrane ER [82, 97]. Competitive binding studies showed that binding to GPR30 is specific 
for E2, environmental estrogens, and ER antiestrogens (ICI 182,780, tamoxifen), whereas the 
potent ER agonist, diethylstilbestrol, and other classes of steroids showed no displacement of 
[3H]-E2 over a wide range of concentrations [82, 98]. 
 
At about the same time our initial characterization of GPR30 was published, a paper from Eric 
Prossnitz’s research group employing E2 conjugated to a fluorescent label showed that the E2-
conjugate bound the GPR30 with the characteristics of a membrane ER [66]. Confirmation that 
GPR30 is a membrane ER by the two research groups working independently provided the 
impetus for further research on the receptor. However, the cellular localization of GPR30 would 
 14 
remain unresolved as Eric’s studies observed GPR30 is expressed predominantly and activated 
intracellularly [66, 99], in contrast to our results demonstrating it is activated on the cell surface 
[82, 83].    
 
Interestingly, the ER antiestrogens ICI 182,780 and tamoxifen were found to act as GPER 
agonists, mimicking the E2-induced increase in cAMP production [82]. The finding that several 
environmental estrogens, including bisphenol A, nonylphenol, genistein, zearalenone, display 
relatively high binding affinities for GPER and act as agonists to increase cAMP synthesis [98], 
provided an early indication that these compounds can disrupt nongenomic estrogen actions 
through the receptor. Recently, we found that an E2 metabolite, the catecholestrogen 2-
hydroxy-E2, binds with high affinity to zebrafish GPER and acts and a GPER antagonist, 
reversing E2 maintenance of oocyte meiotic arrest in this species [100]. 
 
It has been proposed that GPER may also act as an aldosterone receptor based on the 
observation that GPER expression is involved in aldosterone stimulation of ERK1/2 
phosphorylation [101, 102], although direct evidence that GPER binds aldosterone was lacking. 
In detailed binding experiments, we did not detect any specific [3H]-aldosterone binding to 
plasma membrane fractions of mouse kidneys that have high GPER expression, or to HEK293 
cells expressing recombinant GPER, both of which displayed high binding to [3H]-E2 [103]. 
Aldosterone and several mineralocorticoid receptor antagonists also did not compete with [3H]-
E2 binding to GPER, which suggests that the interactions of aldosterone with GPER do not 
involve direct binding to the ligand-binding region of the receptor. Consistent with this notion, 
work by Maggiolini’s group has recently shown cross-talk between GPER and MR in mediating 
the effects of aldosterone [104]. 
 
Recent research in our laboratory by Yefei Pang and others has focused on the characteristics 
and reproductive functions of GPER in fish oocytes. Despite approximately 450 million years of 
divergent evolution of human and teleost GPERs, their receptor binding characteristics 
including steroid specificity are remarkably similar [84, 105]. In addition, the human and fish 
receptors are directly coupled to the same G protein (Gs) and activate the same signaling 
pathways (adenylyl cyclase/cAMP and EGFR/MAPK) [105, 106]. These comparative studies 
suggest the membrane ER activity of GPER is its fundamental, conserved primary physiological 
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function in vertebrates. It is not known, though, whether the reproductive functions of GPER 
identified in fish are shared by other vertebrates.  
  
Pharmacology and physiology of GPER 
E. R. Prossnitz   
 
Having studied G protein-coupled receptor structure/function relationships and signaling 
pathways in the context of neutrophil activation by chemoattractants since 1989 [107-122], I 
was immediately intrigued with the idea of a GPCR functioning as an estrogen receptor in 2002 
based on the then recent review of GPR30 by Ed Filardo [79].  This work had first been 
presented to a group of investigators at UNM by Kim Leslie, who was organizing an NCI 
SPORE application on endometrial cancer.  We formed a working group in late 2002 to begin to 
develop a project to examine the potential contribution of GPR30 to endometrial function and 
carcinogenesis. Towards that goal, I requested a clone of GPR30 from Ron Weigel (due to his 
relative geographical proximity), who reported the cloning of GPCR-Br (i.e. GPR30) in 1997 
[46]. The original team at UNM included Larry Sklar, with whom I had long been collaborating 
on chemoattractant GPCR function [123] , as well as the development of high throughput flow 
cytometry [124], since our days at the Scripps Research Institute, and Tudor Oprea, an expert 
in cheminformatics, who had recently arrived from AstraZeneca [125, 126].  Larry Sklar soon 
introduced me to Jeffrey Arterburn at New Mexico State University, a synthetic organic chemist, 
who by chance was already working of estrogen derivatives for imaging purposes [127, 128]. 
This group of individuals, along with highly talented post-doctoral fellows, Chetana Revankar in 
my lab, and Cristian Bologa in the Oprea group, formed the basis of the team that initially 
explored GPER function in cells [66] and soon screened for GPER-selective ligands [85].  It 
was Chetana Revankar, who showed me our first image of GPR30-RFP expressed in COS7 
cells, which revealed a completely unexpected predominantly intracellularly localized GPER 
(Figure 4), an observation that would later be confirmed in many, but not all, cell types with 
antibodies detecting endogenous GPER [66], and manually carried out the screening of the top 
100 estrogen-like compounds (computationally identified by Tudor Oprea from a library of 
10,000 compounds at UNM).  The GPER-selective compound, later named G-1, was #92 [85]; 
one can only wonder how things might have been different had it been #101!   In connection 
with the original Endometrial SPORE application, I was also introduced to Harriet Smith, a 
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gynecologic oncologist at UNM, with whom I would work to examine the prognostic potential of 
GPER expression in endometrial and ovarian cancers [129, 130]. It is perhaps ironic that our 
first publication on GPER, describing E2 binding to GPER and differential signaling by GPER 
and ER, was submitted to Science in August 2004 [66], within about a week of the paper by 
Peter Thomas and Ed Filardo, describing similar findings using entirely different approaches 
[82]. 
 
Recognizing that a fundamental question regarding GPER was its physiological role(s) in health 
and disease states, I realized that we needed to expand our cell-based studies to animal 
models, an area in which I was not experienced. So it was with great fortune that I discussed 
our work with my departmental colleague Helen Hathaway, an expert on the development of the 
mammary gland and murine models of disease [131].  In 2006, I was contacted by and soon (in 
2008) met Matthias Barton at a drug discovery meeting in Dubai, beginning a more than 10-
year collaboration [70, 132-147].  Various combinations of these individuals (along with superb 
graduate students, post-docs and technicians) would be central to our studies over the years to 
demonstrate that 1) GPER-expressing cells exhibited binding of a fluorescent estrogen 
derivative that colocalized with GPER to intracellular membranes (endoplasmic reticulum and 
Golgi apparatus) (Arterburn, Sklar, [66]); 2) only cell permeable estrogen derivatives rapidly 
activate GPER, suggesting intracellular GPER is functionally active (Arterburn, [99]); 3) GPER-
selective agonists and antagonists, that do not interact with the classical estrogen receptors, 
can be identified (Oprea, Sklar, Arterburn, [85, 86, 148, 149]); 4) GPER can be visualized in 
vivo through the use of novel radio-imaging agents (Arterburn, [150-155]);  5) using murine 
models, including GPER knockout mice, GPER plays important roles in both breast and 
endometrial cancer (but not uterine imbibition for example) (Hathaway, [86, 156-158]) as well as 
in metabolism (Hathaway, [159]) and vascular biology and disease (Barton, [70, 134, 139-142, 
145-147, 160, 161]); 6) GPER is prognostic for survival in both endometrial and ovarian cancers 
(Smith, [129, 130]) and 7) GPER is critical in aging through its regulation of superoxide 
production via Nox1 (Barton, [162]).  Our work to understand the roles of GPER in metabolism 
[163] and vascular biology [71] and the potential clinical benefits of GPER-selective agonists 
and antagonists [149] are reviewed elsewhere in this special issue.  My progress in this field 
over the years has not only been made possible by these many individuals, as well as gifted 
graduate students, technicians and post-docs, but also the co-authors of this article.  In 
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retrospect, I also believe that my background in GPCR molecular pharmacology provided me 
with a fresh unbiased viewpoint, influenced little by the dogma of nuclear estrogen receptors, 
that facilitated much of our progress in the field. As a final thought regarding serendipity in 
science, it was not until working on GPER for some time that I realized, upon searching for new 
publications by Ed Filardo in Pubmed, that Ed and I had both been post-docs at Scripps in the 
early 1990’s – in fact in neighboring labs! 
 
Transcriptional regulation by GPER  
M. Maggiolini  
 
Working in the years 1998-1999 as a visiting professor in Didier Picard’s lab at the Université 
de Genève, Switzerland, I had my first opportunity to provide novel insights into estrogen 
receptor (ER)-mediated functions in breast cancer [164, 165], and subsequently to demonstrate 
that certain phytoestrogens may elicit stimulatory effects in this malignancy by activating ERs 
[166, 167]. Further searching for the multifaceted aspects of estrogen signaling, it was intriguing 
how I came across GPER. Unexpectedly, ER-negative (but GPER-positive) SKBr3 breast 
cancer cells displayed relevant biological responses upon estrogen/phytoestyrogen exposure 
[168]. Initially, it was challenging to understand our results in the context of existing paradigms. 
However, the initial studies of Filardo’s group on GPER helped us to explore new mechanisms, 
as the silencing of GPER abrogated the effects of the aforementioned compounds [168].  One 
important aspect of these investigations was that agonist-activated GPER engages the 
EGFR/MAPK signal transduction pathway resulting in the rapid transcriptional activation of the 
oncogene c-FOS, which was thereafter used as a molecular sensor of GPER action in other cell 
contexts such as thyroid and endometrial tumor cells [169, 170]. Working together with Eric 
Prossnitz (University of New Mexico, USA), we then ascertained that in GPER- and ER-positive 
ovarian cancer cells, 17β-estradiol and the selective GPER ligand G-1 upregulated several 
estrogen-responsive genes such as c-FOS, pS2, and cyclins A, D1 and E; in contrast however, 
progesterone receptor (PR) only responded to E2 [171]. These data, together with the results 
obtained by silencing experiments and growth assays, suggested that a functional interaction 
between GPER and ERα may occur when both receptors are expressed in tumor cells [171].  
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In the framework of my meaningful and long-standing collaboration with Didier Picard, it was 
fortuitous that a post-doc (D. Prakash Pandey) from his group came to my lab and, working 
together with my collaborators, defined the gene signature prompted by estrogenic GPER 
signaling [172]. Interestingly, gene responses included a first tier of transcription factors 
including SRF, CREB, and members of the ETS family followed by a second wave of 
transcription factors such as FOS, JUN, CTGF, EGR1, ATF3, C/EBPd and NR4A2 ([172]; see 
also [173]). These findings allowed us to discover a second critical molecular sensor of GPER 
action beyond c-fos, namely CTGF, as highlighted in several subsequent studies (reviewed in 
[174]).  
 
Thereafter, we sought to determine the role of GPER in estrogen-mediated function with 
respect to the main components of the tumor microenvironment, cancer-associated fibroblasts 
(CAFs), which drive crucial malignant features such as invasion, metastasis and angiogenesis 
[97-108].  In a recent study [175], we found that ligand-activated GPER generates a feed-
forward loop coupling IL1β induction by CAFs to IL1R1 expression by cancer cells, thereby 
promoting the up-regulation of IL1β/IL1R1 target genes, namely PTGES, COX2, RAGE and 
ABCG2. As a biological counterpart, the functional liaison between these two cell types 
triggered migration and invasive features in breast cancer cells, including fibroblastoid 
cytoarchitecture and F-actin reorganization. These data therefore contributed to the further 
appreciation of the role elicited by GPER toward pro-tumorigenic inflammatory phenotypes. In 
addition, we discovered that low oxygen tension, a critical factor in the hypoxic tumor 
environment, triggers, through HIF-1α, the induction of both GPER and its downstream target 
CTGF [176]. Similarly, it was remarkable to discover that GPER-mediated signaling up-
regulates HIF1α and VEGF, further supporting the involvement of GPER in cancer 
angiogenesis [177, 178].  
 
As previous studies had attempted to determine whether GPER may be considered a 
prognostic factor in cancer outcome/survival [179, 180], a better understanding of its regulation 
was warranted. In this regard, our early as well as more recent studies have provided notable 
data regarding the potential of diverse growth factors and cognate receptors to modulate 
GPER, engaging its downstream signaling towards the stimulation of aggressive cancer 
features [181-188]. Such studies gave us the opportunity to establish a great collaboration with 
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Antonino Belfiore at the University of Catanzaro, Italy, to examine the molecular signals linking 
the insulin-like growth factor-I (IGF-I)/IGF-I receptor (IGF-IR) system and GPER, providing 
further insights on the well-established actions played by the IGF axis in cancer.  Over the 
years, our studies of the actions of estrogen through GPER support the critical roles played by 
several other members of the GPCR family in cancer development and progression [189]. Last 
but not least, I must acknowledge the fundamental role played by the many young people who 
contributed to the aforementioned research topics, some of which are still members of our 
group, whereas others are working abroad.  
 
Concluding thoughts on future research: the next 20 years  
 
The history of estrogen has been replete with astounding discoveries and advances in medical 
care.  Its critical roles in reproduction/fertility/menopause and breast cancer have resulted in 
perhaps some of the most transformative clinical advances of our time, namely the 
induction/prevention of conception (birth control), the alleviation of post-menopausal symptoms 
and diseases (menopausal hormone therapy), and the treatment of ER-positive breast cancer 
[27, 190].  Together, modulating the (patho)physiology of estrogen and its receptors has 
benefitted hundreds of millions of women.  Despite our growing knowledge of the mechanisms 
of estrogen action, much remains to be understood. Although some of the first actions of 
estrogen to be described would today be defined as rapid or non-genomic, subsequent 
decades or work focused on the transcriptional or genomic actions of estrogen, before a 
resurgence of investigations into rapid effects in the 1990s and 2000s.  Today, it is clear that 
the combined rapid and genomic effects of estrogen are critical to its overall function, and that 
even in the absence of estrogen (i.e. in the unliganded state), "classical" estrogen receptors 
[191] and GPER [162] exert constitutive (i.e. ligand-independent) functions on physiology and 
disease [192, 193].  However, these interactions are complex and involve multiple receptor 
types, both soluble and membrane associated.  The development of selective ligands that 
either activate or inhibit individual receptors not only further our basic understanding of estrogen 
biology but may also represent important clinical opportunities for drug development [142, 146, 
194, 195].  In the next 20 years, much remains to be elucidated regarding the actions of GPER 
and the possibility of diagnostics and therapeutics targeting the pathways that are regulated by 
this receptor. 
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In Memoriam: Oliver Smithies 
As the authors were finalizing this manuscript, they learned of the death of Oliver 
Smithies (1925-2017) on January 10 [196, 197]. Smithies, like Mario Capecchi and Sir 
Martin Evans, had pioneered the generation of transgenic animals using embryonic 
stem cells [198, 199], for which they received the 2007 Nobel Prize in Physiology or 
Medicine [200]. The technology introduced by Smithies was essential for studying the 
role of GPER in physiology and disease, as it was used to generate the first GPER-
deficient mouse in 2007 [69, 70, 131, 162, 201]. 
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Figure Legends 
 
Figure 1.  Biologist Clara M. Szego, PhD. Szego was born in Budapest, Hungary, on March 
23, 1916. She was a pioneer in the study of estrogen biology (beginning in the 1940s) and in 
the rapid responses to estrogen (in the 1960s and 1970s), making seminal contributions in both 
fields. In 1956, Dr. Szego became a Guggenheim fellow while working at the University of 
California, Los Angeles, and in 1957, she was honored as one of ten Women of the Year by the 
Los Angeles Times. The photograph was taken in 1957 and provided by the Los Angeles 
Times. 
 
 
Figure 2.  Rapid non-genomic effects of estrogen in a human coronary artery ring 
(Barton). Shown on the left is an organ bath allowing ex vivo study of vascular tone of an intact 
human coronary artery (4 mm in diameter) obtained during cardiac transplantation (suspended 
between to steel hooks in physiological salt solution at 37°C). The right panel shows an original 
tracing of the first ever recorded response to 17-estradiol of a human coronary artery obtained 
from a female patient. The cardiac transplantation and experiment took place on May 1, 1992. 
The left anterior descending (LAD) artery was obtained from a 22 year-old women requiring a 
heart transplant after developing dilated cardiomyopathy (DCM) and severe heart failure as a 
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complication of a viral infection. Upper panel: Coronary artery tone was recorded after exposure 
to a contractile substance (prostaglandin F2). Once a stable plateau was reached, a single 
concentration of the non-selective estrogen receptor agonist 17-estradiol (E2, 3 µmol/L) was 
added to the bath, causing immediate and complete relaxation of the pre-contracted artery. By 
contrast, the solvent control ethanol (ETOH, lower panel) had only marginal effects on arterial 
tone. Within 30 min, E2 also increased coronary artery cAMP content [57]. At the time of the 
experiment, only a single ER protein was known; neither ER nor GPER had been cloned, and it 
was later shown that the rapid dilator response [70] and cAMP increase [58, 202] involve 
GPER. Left panel: original organ chamber showing a human coronary artery suspended from a 
Hugo Sachs force transducer; photograph taken by the author (M.B.) at the Division of 
Cardiology of Hannover Medical School in 1991. Right panel reproduced from reference [60]. 
 
Figure 3.  The first cloning of a cDNA for a receptor that would later be called GPR30 and 
eventually GPER (Lolait).  The cloning of the human GPR30 (GPER) cDNA was first 
published in 1996 [44] as detailed in the text. In fact, this cDNA (designated clone 47-2) was 
isolated over 4 years earlier, as evidenced in a note from the first (Christer Owman) to senior 
(Stephen Lolait) author indicating that the clone was isolated prior to mid-Feb 1992. The note 
details the DNA concentrations of sets of oligonucleotides (48 base pairs) specific for a number 
of cDNA clones encoding some orphan GPCRs isolated in the lab around the same time. The 
GPER clone 47-2 and oligonucleotides Lym 1 and Lym 2 (in red) are detailed in the publication. 
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Clone 21-9 encoded a GPCR that was later deorphanised by others as the leukotriene B4 
receptor (LTB4R) [203]. 
 
Figure 4.  The first image of GPR30 expressed in COS7 cells (Prossnitz).  In order to 
localize the site(s) of GPR30 expression, the cDNA for GPR30 was fused in frame at the 3’ (C-
terminal) end to GFP (green fluorescent protein) or mRFP (monomeric red fluorescent protein 
[204], shown in red) and subcloned in pcDNA3.  COS7 cells were transfected with the plasmid 
construct and imaged by confocal microscopy, using TO-PRO-3 as a nuclear stain (blue) as in 
[66].  This first image to test the new plasmid construct came as a great surprise as GPCRs 
(see localization of 2-adrenergic receptor in Fig. 1A of [66]) are usually expressed 
predominantly at the plasma membrane (with some expression often detectable in the Golgi 
apparatus, as a result of accumulation during processing and transport to the plasma 
membrane).  On the contrary, however, the fluorescent protein fusions of GPR30 showed a 
predominantly intracellular localization, being expressed in the endoplasmic reticulum and Golgi 
apparatus with essentially no detectable receptor at the plasma membrane.  Although at first we 
suspected the C-terminal fusion of fluorescent proteins might be impeding processing and 
transport, staining of endogenously expressed GPR30 with newly generated antibodies would 
reveal a similar expression pattern. Overtime, it would become clear that although most cells 
exhibit significant localization of GPER intracellularly, GPER does traffic to the plasma 
membrane (to varying extents, likely dependent on cell type) [82, 83, 105], from where it is 
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constitutively internalized (in an apparently ligand-independent manner) leading to retrograde 
transport to intracellular membrane compartments, including the endoplasmic reticulum [88, 
205, 206].  It is perhaps not entirely surprising that GPER can function intracellularly [99], as 
estrogen is freely membrane permeable and must “find its way” to the nucleus to activate the 
classical estrogen receptors ER and ER. 
 
